Shares of Metsera Inc. (MTSR) have gained 6.8% over the past four weeks to close the last trading session at $35.32, but ...

Metsera is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could ...

While the year started out as cautiously optimistic, stemming from the peak of biotech initial public offering (IPO) activity ...

If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera. After emerging from stealth with a $290 ...

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs, cueing up an IPO.

Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Methode Electronics posted adjusted loss of 77 cents per share, missing market estimates of earnings of 4 cents per share, ...

Take a look at these three top-ranked, best-performing and well-managed mutual funds if you're looking to maximize your retirement portfolio returns.

Merck & Co. agreed on Wednesday to acquire Verona Pharma for $107 per American Depository Share (ADS) for a total transaction ...

See the latest Maze Therapeutics Inc stock price (MAZE:XNAS), related news, valuation, dividends and more to help you make your investing decisions.